Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease
Retatrutide's profile will sharpen as the remaining seven TRIUMPH trials report over 2026
It is important to stay flexible and listen to your body's signals
GLP-1 Receptor Agonist Exposure During Pregnancy: A Systematic Review and Meta-Analysis of Adverse Pregnancy Outcomes
The short-acting GLP-1 receptor agonists primarily lower postprandial blood glucose levels through inhibition of gastric emptying, whereas the long-acting compounds have a stronger effect on fasting glucose levels, which is mediated predominantly through their insulinotropic and glucagonostatic actions
For individuals who do not respond to GLP-1, this tailored, phenotype-driven methodology within a stepped-care framework guarantees more precise and efficacious interventions, affirming the early use of medication as a scientifically substantiated and personalised strategy rather than a mere pragmatic option